OKYO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 20:38):

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom...

Stats
Dzisiejszy wolumen	12 702.00
Średni wolumen	170 729
Kapitalizacja rynkowa	50.85M
EPS	$0 ( 2023-12-28 )
Następna data zysków	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.51
ATR14	$0.0220 (1.44%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-27	Cerrone Gabriele M	Buy	70 071	Ordinary Shares
2023-10-23	Cerrone Gabriele M	Buy	499 468	Ordinary Shares
2023-09-15	Brancaccio John P	Buy	16 670	Ordinary Shares
2022-05-19	Cerrone Gabriele M	Buy	5 800 000	Ordinary Shares
2022-05-19	Jacob Gary S	Buy	12 500	American Depositary Shares

INSIDER POWER
-54.58
Last 18 transactions
Buy: 8 086 209 \| Sell: 58 400 000

OKYO Pharma Limited Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OKYO Pharma Limited Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-3 797.00 (0.00 %)
EPS:	$-0.600

FY	2023
Przychody:	$0
Zysk brutto:	$-3 797.00 (0.00 %)
EPS:	$-0.600

FY	2022
Przychody:	$0
Zysk brutto:	$-2 423.01 (0.00 %)
EPS:	$-0.00550

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.290

Financial Reports:

No articles found.

OKYO Pharma Limited

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Aktualne aktualizacje dla OKYO Pharma Limited [OKYO]

Upcoming Earnings Alert